Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–oxaliplatine combination (XELOX) in HCC patients. First-line chemotherapy with XELOX reg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Boige, V, Raoul, J-L, Pignon, J-P, Bouché, O, Blanc, J-F, Dahan, L, Jouve, J-L, Dupouy, N, Ducreux, M
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2007
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360397/
https://ncbi.nlm.nih.gov/pubmed/17876335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603956
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge